{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:19:40Z","timestamp":1789507180100,"version":"build-2803163510"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.vaccine.2025.128136","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T16:58:19Z","timestamp":1766077099000},"page":"128136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Herpes zoster mRNA vaccine elicits superior immune responses over licensed vaccines with a favorable safety profile in animal models"],"prefix":"10.1016","volume":"72","author":[{"given":"Yan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoyi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhendong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaru","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minhe","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronglin","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yucai","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.vaccine.2025.128136_bb0005","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1128\/CMR.9.3.361","article-title":"Varicella-zoster virus","volume":"9","author":"Arvin","year":"1996","journal-title":"Clin Microbiol Rev"},{"issue":"3","key":"10.1016\/j.vaccine.2025.128136_bb0010","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrmicro3215","article-title":"Molecular mechanisms of varicella zoster virus pathogenesis","volume":"12","author":"Zerboni","year":"2014","journal-title":"Nat Rev Microbiol"},{"issue":"suppl_2","key":"10.1016\/j.vaccine.2025.128136_bb0015","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1093\/infdis\/jiy403","article-title":"Immunobiology of varicella-zoster virus infection","volume":"218","author":"Laing","year":"2018","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2025.128136_bb0020","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.cger.2016.02.011","article-title":"Herpes Zoster","volume":"32","author":"Schmader","year":"2016","journal-title":"Clin Geriatr Med"},{"issue":"10","key":"10.1016\/j.vaccine.2025.128136_bb0025","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1212\/WNL.0b013e3182a3516e","article-title":"The global epidemiology of herpes zoster","volume":"81","author":"Yawn","year":"2013","journal-title":"Neurology"},{"issue":"16","key":"10.1016\/j.vaccine.2025.128136_bb0030","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1056\/NEJMcp1403062","article-title":"Clinical practice. Postherpetic neuralgia","volume":"371","author":"Johnson","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.vaccine.2025.128136_bb0035","doi-asserted-by":"crossref","DOI":"10.3390\/v14020192","article-title":"Herpes zoster: a review of clinical manifestations and management","volume":"14","author":"Patil","year":"2022","journal-title":"Viruses"},{"issue":"6","key":"10.1016\/j.vaccine.2025.128136_bb0040","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1080\/21645515.2020.1847582","article-title":"A systematic literature review of herpes zoster incidence worldwide","volume":"17","author":"van Oorschot","year":"2021","journal-title":"Hum Vaccin Immunother"},{"issue":"4","key":"10.1016\/j.vaccine.2025.128136_bb0045","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1177\/2051013615599151","article-title":"Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective","volume":"3","author":"Johnson","year":"2015","journal-title":"Ther Adv Vaccines"},{"issue":"3","key":"10.1016\/j.vaccine.2025.128136_bb0050","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s40259-016-0180-7","article-title":"Shingles (herpes zoster) vaccine (Zostavax(R)): a review in the prevention of herpes zoster and postherpetic neuralgia","volume":"30","author":"Keating","year":"2016","journal-title":"BioDrugs"},{"issue":"4","key":"10.1016\/j.vaccine.2025.128136_bb0055","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1590\/1516-3180.20141324T1","article-title":"Vaccines for preventing herpes zoster in older adults","volume":"132","author":"Leme","year":"2014","journal-title":"Sao Paulo Med J"},{"issue":"22","key":"10.1016\/j.vaccine.2025.128136_bb0060","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.vaccine.2025.128136_bb0065","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/cid\/cir970","article-title":"Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years","volume":"54","author":"Schmader","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2025.128136_bb0070","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01816-24","article-title":"Insights into pathologic mechanisms occurring during serious adverse events following live zoster vaccination","volume":"99","author":"Kennedy","year":"2025","journal-title":"J Virol"},{"issue":"20","key":"10.1016\/j.vaccine.2025.128136_bb0075","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1016\/j.vaccine.2012.01.088","article-title":"Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice","volume":"30","author":"Dendouga","year":"2012","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2025.128136_bb0080","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1080\/14760584.2018.1495565","article-title":"Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention","volume":"17","author":"Lecrenier","year":"2018","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"10.1016\/j.vaccine.2025.128136_bb0085","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1128\/JVI.00913-08","article-title":"Deletion of the first cysteine-rich region of the varicella-zoster virus glycoprotein E ectodomain abolishes the gE and gI interaction and differentially affects cell-cell spread and viral entry","volume":"83","author":"Berarducci","year":"2009","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2025.128136_bb0090","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.cell.2006.08.046","article-title":"Insulin degrading enzyme is a cellular receptor mediating varicella-zoster virus infection and cell-to-cell spread","volume":"127","author":"Li","year":"2006","journal-title":"Cell"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2025.128136_bb0095","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1086\/514268","article-title":"Intracellular transport of varicella-zoster glycoproteins","volume":"178","author":"Wang","year":"1998","journal-title":"J Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2025.128136_bb0100","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.vaccine.2025.128136_bb0105","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"issue":"suppl_2","key":"10.1016\/j.vaccine.2025.128136_bb0110","doi-asserted-by":"crossref","first-page":"S127","DOI":"10.1093\/infdis\/jiy382","article-title":"Herpes Zoster Vaccines","volume":"218","author":"Cunningham","year":"2018","journal-title":"J Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2025.128136_bb0115","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1001\/jamainternmed.2021.6227","article-title":"Risk of Guillain-Barr\u00e9 syndrome following recombinant zoster vaccine in Medicare beneficiaries","volume":"181","author":"Goud","year":"2021","journal-title":"JAMA Intern Med"},{"issue":"44","key":"10.1016\/j.vaccine.2025.128136_bb0120","doi-asserted-by":"crossref","first-page":"6776","DOI":"10.1016\/j.vaccine.2019.09.031","article-title":"VZV-specific cell-mediated immunity, but not humoral immunity, correlates inversely with the incidence of herpes zoster and the severity of skin symptoms and zoster-associated pain: the SHEZ study","volume":"37","author":"Asada","year":"2019","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2025.128136_bb0125","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01375-18","article-title":"Reactivation of simian varicella virus in Rhesus macaques after CD4 T cell depletion","volume":"93","author":"Traina-Dorge","year":"2019","journal-title":"J Virol"},{"issue":"11","key":"10.1016\/j.vaccine.2025.128136_bb0130","first-page":"2151","article-title":"Association of reduced CD4 T cell responses specific to varicella zoster virus with high incidence of herpes zoster in patients with systemic lupus erythematosus","volume":"31","author":"Park","year":"2004","journal-title":"J Rheumatol"},{"issue":"15","key":"10.1016\/j.vaccine.2025.128136_bb0135","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/j.vaccine.2014.01.019","article-title":"Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study","volume":"32","author":"Chlibek","year":"2014","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2025.128136_bb0140","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1093\/infdis\/jis497","article-title":"A phase 1\/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults","volume":"206","author":"Leroux-Roels","year":"2012","journal-title":"J Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2025.128136_bb0145","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","article-title":"mRNA vaccines for infectious diseases: principles, delivery and clinical translation","volume":"20","author":"Chaudhary","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.vaccine.2025.128136_bb0150","doi-asserted-by":"crossref","unstructured":"Kowalzik F, Schreiner D, Jensen C, Teschner D, Gehring S et al.: mRNA-Based Vaccines. Vaccines (Basel) 2021, 9(4).","DOI":"10.3390\/vaccines9040390"},{"issue":"36","key":"10.1016\/j.vaccine.2025.128136_bb0155","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.1016\/j.vaccine.2020.06.062","article-title":"Immunogenicity generated by mRNA vaccine encoding VZV gE antigen is comparable to adjuvanted subunit vaccine and better than live attenuated vaccine in nonhuman primates","volume":"38","author":"Monslow","year":"2020","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2025.128136_bb0160","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines10111807","article-title":"Development of bivalent mRNA vaccines against SARS-CoV-2 variants","volume":"10","author":"Li","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2025.128136_bb0165","series-title":"National Research Council Committee for the update of the guide for the care and use of laboratory animals. Guide for the care and use of laboratory animals","year":"2011"},{"issue":"1","key":"10.1016\/j.vaccine.2025.128136_bb0170","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1073\/pnas.0912373107","article-title":"Functions of the unique N-terminal region of glycoprotein E in the pathogenesis of varicella-zoster virus infection","volume":"107","author":"Berarducci","year":"2009","journal-title":"Proc Natl Acad Sci"},{"issue":"22","key":"10.1016\/j.vaccine.2025.128136_bb0175","doi-asserted-by":"crossref","first-page":"12406","DOI":"10.1128\/JVI.78.22.12406-12415.2004","article-title":"Functions of the C-terminal domain of varicella-zoster virus glycoprotein E in viral replication in vitro and skin and T-cell tropism in vivo","volume":"78","author":"Moffat","year":"2004","journal-title":"J Virol"},{"issue":"10","key":"10.1016\/j.vaccine.2025.128136_bb0180","doi-asserted-by":"crossref","first-page":"6563","DOI":"10.1128\/jvi.70.10.6563-6575.1996","article-title":"Targeting of glycoprotein I (gE) of varicella-zoster virus to the trans-Golgi network by an AYRV sequence and an acidic amino acid-rich patch in the cytosolic domain of the molecule","volume":"70","author":"Zhu","year":"1996","journal-title":"J Virol"},{"issue":"6","key":"10.1016\/j.vaccine.2025.128136_bb0185","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkaa070","article-title":"N 1-Methylpseudouridine substitution enhances the performance of synthetic mRNA switches in cells","volume":"48","author":"Parr","year":"2020","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"10.1016\/j.vaccine.2025.128136_bb0190","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.tim.2022.07.008","article-title":"T cell immunity in HSV-1- and VZV-infected neural ganglia","volume":"31","author":"Boeren","year":"2023","journal-title":"Trends Microbiol"},{"issue":"13","key":"10.1016\/j.vaccine.2025.128136_bb0195","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02127-19","article-title":"Persistence of varicella-zoster virus-specific plasma cells in adult human bone marrow following childhood vaccination","volume":"94","author":"Eberhardt","year":"2020","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2025.128136_bb0200","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41541-024-00980-3","article-title":"Preclinical immunogenicity and safety of hemagglutinin-encoding modRNA influenza vaccines","volume":"9","author":"Hauguel","year":"2024","journal-title":"NPJ Vaccines"},{"issue":"2","key":"10.1016\/j.vaccine.2025.128136_bb0205","article-title":"Toxicological assessments of a pandemic COVID-19 vaccine-demonstrating the suitability of a platform approach for mRNA vaccines","volume":"11","author":"Rohde","year":"2023","journal-title":"Vaccines (Basel)"},{"issue":"2","key":"10.1016\/j.vaccine.2025.128136_bb0210","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/0300985817738095","article-title":"Safety evaluation of lipid nanoparticle-formulated modified mRNA in the Sprague-Dawley rat and Cynomolgus monkey","volume":"55","author":"Sedic","year":"2018","journal-title":"Vet Pathol"},{"issue":"13","key":"10.1016\/j.vaccine.2025.128136_bb0215","doi-asserted-by":"crossref","first-page":"495","DOI":"10.15585\/mmwr.mm7013e3","article-title":"Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers - eight U.S. locations, December 2020-march","volume":"70","author":"Thompson","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"10.1016\/j.vaccine.2025.128136_bb0220","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41541-024-00925-w","article-title":"Safety and efficacy assessment of an mRNA rabies vaccine in dogs, rodents, and cynomolgus macaques","volume":"9","author":"Li","year":"2024","journal-title":"NPJ Vaccines"},{"issue":"25","key":"10.1016\/j.vaccine.2025.128136_bb0225","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1016\/j.vaccine.2019.04.074","article-title":"mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials","volume":"37","author":"Feldman","year":"2019","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2025.128136_bb0230","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s40588-016-0044-4","article-title":"Varicella-zoster virus glycoproteins: entry, replication, and pathogenesis","volume":"3","author":"Oliver","year":"2016","journal-title":"Curr Clin Microbiol Rep"},{"issue":"19","key":"10.1016\/j.vaccine.2025.128136_bb0235","doi-asserted-by":"crossref","first-page":"9481","DOI":"10.1128\/JVI.00533-06","article-title":"Essential functions of the unique N-terminal region of the varicella-zoster virus glycoprotein E ectodomain in viral replication and in the pathogenesis of skin infection","volume":"80","author":"Berarducci","year":"2006","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2025.128136_bb0240","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1006\/viro.2002.1556","article-title":"The requirement of varicella zoster virus glycoprotein E (gE) for viral replication and effects of glycoprotein I on gE in melanoma cells","volume":"304","author":"Mo","year":"2002","journal-title":"Virology"},{"issue":"2","key":"10.1016\/j.vaccine.2025.128136_bb0245","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1006\/viro.1995.0064","article-title":"Identification of immunodominant regions and linear B cell epitopes of the gE envelope protein of varicella-zoster virus","volume":"214","author":"Fowler","year":"1995","journal-title":"Virology"},{"issue":"3","key":"10.1016\/j.vaccine.2025.128136_bb0250","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1089\/vim.1991.4.151","article-title":"Human T cells recognize multiple epitopes of an immediate early\/tegument protein (IE62) and glycoprotein I of varicella zoster virus","volume":"4","author":"Bergen","year":"1991","journal-title":"Viral Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2025.128136_bb0255","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1006\/viro.1998.9313","article-title":"Antigenic variation of varicella zoster virus fc receptor gE: loss of a major B cell epitope in the ectodomain","volume":"249","author":"Santos","year":"1998","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.vaccine.2025.128136_bb0260","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41541-024-00865-5","article-title":"Potent and long-lasting humoral and cellular immunity against varicella zoster virus induced by mRNA-LNP vaccine","volume":"9","author":"Bhattacharya","year":"2024","journal-title":"NPJ Vaccines"},{"issue":"1","key":"10.1016\/j.vaccine.2025.128136_bb0265","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41541-025-01093-1","article-title":"A highly stable lyophilized mRNA vaccine for herpes zoster provides potent cellular and humoral responses","volume":"10","author":"Munoz-Moreno","year":"2025","journal-title":"NPJ Vaccines"},{"issue":"3","key":"10.1016\/j.vaccine.2025.128136_bb0270","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/j.1365-2249.2008.03633.x","article-title":"Varicella zoster virus glycoprotein E-specific CD4+ T cells show evidence of recent activation and effector differentiation, consistent with frequent exposure to replicative cycle antigens in healthy immune donors","volume":"152","author":"Malavige","year":"2008","journal-title":"Clin Exp Immunol"},{"issue":"10","key":"10.1016\/j.vaccine.2025.128136_bb0275","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1172\/JCI121484","article-title":"Th1 memory differentiates recombinant from live herpes zoster vaccines","volume":"128","author":"Levin","year":"2018","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.vaccine.2025.128136_bb0280","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1046\/j.1365-2249.2003.02061.x","article-title":"Local immune responses and systemic cytokine responses in zoster: relationship to the development of postherpetic neuralgia","volume":"131","author":"Zak-Prelich","year":"2003","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2025.128136_bb0285","doi-asserted-by":"crossref","DOI":"10.1080\/22221751.2024.2309985","article-title":"Herpes zoster mRNA vaccine induces superior vaccine immunity over licensed vaccine in mice and rhesus macaques","volume":"13","author":"Huang","year":"2024","journal-title":"Emerg Microbes Infect"},{"issue":"12","key":"10.1016\/j.vaccine.2025.128136_bb0290","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00240-21","article-title":"Comparative antibody responses to the live-attenuated and recombinant herpes zoster vaccines","volume":"95","author":"Schmid","year":"2021","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2025.128136_bb0295","doi-asserted-by":"crossref","first-page":"8029","DOI":"10.2147\/IJN.S464720","article-title":"Heterologous prime-boost immunization strategies using varicella-zoster virus gE mRNA vaccine and adjuvanted protein subunit vaccine triggered superior cell immune response in middle-aged mice","volume":"19","author":"Li","year":"2024","journal-title":"Int J Nanomedicine"},{"issue":"2","key":"10.1016\/j.vaccine.2025.128136_bb0300","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3390\/pathogens2020364","article-title":"Animal models of varicella zoster virus infection","volume":"2","author":"Haberthur","year":"2013","journal-title":"Pathogens"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25014343?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25014343?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T09:27:26Z","timestamp":1768469246000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25014343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":60,"alternative-id":["S0264410X25014343"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.128136","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Herpes zoster mRNA vaccine elicits superior immune responses over licensed vaccines with a favorable safety profile in animal models","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.128136","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128136"}}